# nature portfolio

Corresponding author(s):	XF. Yu, H.Zheng, X. Sun, Y. Ge

Last updated by author(s): Yongshuai Ge

# **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

_				
5	ta:	t١	c†	ics

For	all sta	atistical ana	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Con	ıfirmed	
X		The exact s	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
X		A statemer	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
X	1 1		ical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.
X		A descripti	ion of all covariates tested
X		A descripti	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
X	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)  AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
X	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.		
X	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated			
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
Software and code			
Policy information about <u>availability of computer code</u>			
Da	ita co	ollection	Softwares: N/A
Da	ıta ar	nalysis	Softwares: Python and ImageJ
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.			
Da	ta		

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data are included in supplementary files. Source data has been deposited in Figshare database: 10.6084/m9.figshare.24922572

Research inv	olving human participants, their data, or biological material
	about studies with <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> ion and <u>race, ethnicity and racism</u> .
Reporting on sex a	and gender
Reporting on race other socially rele groupings	
Population charac	cteristics
Recruitment	
Ethics oversight	
Note that full informat	tion on the approval of the study protocol must also be provided in the manuscript.
Field-spe	cific reporting
Please select the on	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of th	he document with all sections, see <a href="mailto:nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>
Life scien	nces study design
All studies must disc	close on these points even when the disclosure is negative.
Sample size	N/A
Data exclusions	N/A
Replication	N/A
Randomization	N/A
Blinding	N/A
Behaviou	ıral & social sciences study design
All studies must disc	close on these points even when the disclosure is negative.
Study description	
Research sample	
Sampling strategy	

Data collection

Timing Data exclusions

Non-participation Randomization

Foological a	valutionary 2 anyiranmantal sciences study design	
	volutionary & environmental sciences study design  these points even when the disclosure is negative.	
Study description	these points even when the disclosure is negative.	
Research sample		
Sampling strategy		
Data collection		
Timing and spatial scale		
Data exclusions		
Reproducibility		
Randomization		
Blinding		
Did the study involve field	d work? Yes No	
Field work, collect	tion and transport	
Field conditions	N/A	
Location	N/A	
Access & import/export	N/A	
Disturbance	N/A	
Reporting for specific materials, systems and methods  We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & experime	·	
n/a Involved in the study  Antibodies	n/a   Involved in the study  ChIP-seq	
Eukaryotic cell lines	Flow cytometry	
Palaeontology and a		
Animals and other o	rganisms	
Dual use research of	f concern	
× Plants		

## Antibodies

Antibodies used

Validation

Eukaryotic cell line	es
Policy information about <u>ce</u>	Il lines and Sex and Gender in Research
Cell line source(s)	
Authentication	
Mycoplasma contamination	on
Commonly misidentified I (See <u>ICLAC</u> register)	ines
Palaeontology and	d Archaeology
Specimen provenance	
Specimen deposition	
Dating methods	
Tick this box to confirm	n that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.
Animals and other	r research organisms
Policy information about <u>stu</u> <u>Research</u>	udies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in
Laboratory animals	Strain: C57BL/6JNifdc; Stock #: 219; Age: 6-8 weeks, procured from Beijing VENTOLIN Experimental Animal Technology Co., Ltd.
Wild animals	No wild animals used
Reporting on sex	This is a male mouse
Field-collected samples	No field collected data
Ethics oversight	All experiment in ethical permits SIAT-ACUC-231108-YGS-SZH-A2338 (Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences)
Note that full information on th	ne approval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about <u>cli</u> All manuscripts should comply	nical studies with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

### Dual use research of concern

Policy information about <u>dual use research of concern</u>

#### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes		
Public health		
National security		
Crops and/or livestocl	k	
Ecosystems		
Any other significant a	area	
Experiments of concern		
Does the work involve any o	of these experiments of concern:	
No Yes		
Demonstrate how to	render a vaccine ineffective	
Confer resistance to t	herapeutically useful antibiotics or antiviral agents	
Enhance the virulence	e of a pathogen or render a nonpathogen virulent	
Increase transmissibil	ity of a pathogen	
Alter the host range o	of a pathogen	
Enable evasion of diag	gnostic/detection modalities	
	ation of a biological agent or toxin	
Any other potentially	harmful combination of experiments and agents	
Plants		
Seed stocks		
Novel plant genotypes		
Authentication		
ChIP-seq		
Data deposition		
	nd final processed data have been deposited in a public database such as <u>GEO</u> .	
Confirm that you have d	eposited or provided access to graph files (e.g. BED files) for the called peaks.	
Data access links		
May remain private before publicati	ion.	
Files in database submission	n (	
Genome browser session (e.g. <u>UCSC</u> )		
Methodology		
Replicates		
Sequencing depth		
Antibodies		
Peak calling parameters		
Data quality		
Software		

Flow Cytometry	
The axis scales are clearly visib	er and fluorochrome used (e.g. CD4-FITC).  ole. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).  h outliers or pseudocolor plots.  of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	
Instrument	
Software	
Cell population abundance	
Gating strategy	
Tick this box to confirm that a	figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance in	naging
	<u>laging</u>
Experimental design  Design type	
Design type  Design specifications	
Behavioral performance measure	
bellavioral performance measure	
Imaging type(s)	
Field strength	
Sequence & imaging parameters	
Area of acquisition	
Diffusion MRI Used	☐ Not used
Preprocessing	
Preprocessing software	
Normalization	
Normalization template	
Noise and artifact removal	
Volume censoring	
Statistical modeling & inferer	nce
Model type and settings	
Effect(s) tested	
Specify type of analysis: Wh	oole brain ROI-based Both

nature portfolio
reporting summa
ımmar

$\rightarrow$	
ଽ	
ч	
s	
Ņ	
	۱

Statistic type for inference		
(See Eklund et al. 2016)		
Correction		
Models & analysis		
n/a Involved in the study		
Functional and/or effective co	onnectivity	
Graph analysis		
Multivariate modeling or pred	lictive analysis	
Functional and/or effective connect	tivity	
Graph analysis		

Multivariate modeling and predictive analysis